134 related articles for article (PubMed ID: 4408206)
1. Effect of calcitonin and hexestrol on urinary excretion of hydroxyproline in a patient with prostatic cancer and bone metastases.
Matsushita Y; Hasegawa K; Sugimura R; Otomo S; Morii H
Endocrinol Jpn; 1974 Apr; 21(2):109-13. PubMed ID: 4408206
[No Abstract] [Full Text] [Related]
2. Urine hydroxyproline excretion--a marker of bone metastases in prostatic carcinoma.
Bishop MC; Fellows GJ
Br J Urol; 1977; 49(7):711-6. PubMed ID: 597712
[TBL] [Abstract][Full Text] [Related]
3. Urinary hydroxyproline excretion in patients with cancer.
Guzzo CE; Pachas WN; Pinals RS; Krant MJ
Cancer; 1969 Aug; 24(2):382-7. PubMed ID: 5796782
[No Abstract] [Full Text] [Related]
4. Urinary hydroxyproline, serum alkaline phosphatase, calcium and phosphorus in patients with bone neoplasms.
Radom S; Zulawski M; Golebiowska D
Pol Med J; 1972; 11(4):809-14. PubMed ID: 4342776
[No Abstract] [Full Text] [Related]
5. Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer.
Rinsho K; Aoyagi K
Tohoku J Exp Med; 1982 Aug; 137(4):461-2. PubMed ID: 7123546
[TBL] [Abstract][Full Text] [Related]
6. Serial spot hydroxyproline/creatinine ratios in metastatic prostatic cancer.
Hopkins SC; Nissenkorn I; Palmieri GM; Ikard M; Moinuddin M; Soloway MS
J Urol; 1983 Feb; 129(2):319-23. PubMed ID: 6834497
[TBL] [Abstract][Full Text] [Related]
7. [Urinary and serum hydroxyproline in the diagnosis of bone metastases of prostatic cancer].
Gasser AB; Jeannet C; Depierre D; Courvoisier B
Schweiz Med Wochenschr; 1981 Feb; 111(8):246-51. PubMed ID: 7233140
[TBL] [Abstract][Full Text] [Related]
8. Relevance of hydroxyproline excretion to bone metastasis in breast cancer.
Gielen F; Dequeker J; Drochmans A; Wildiers J; Merlevede M
Br J Cancer; 1976 Sep; 34(3):279-85. PubMed ID: 974001
[TBL] [Abstract][Full Text] [Related]
9. [Use of urinary hydroxyproline excretion as a marker of bone metastases in prostatic cancer (1)].
Kurokawa K; Imai K; Yamanaka H; Tomaru Y; Kitaura K
Hinyokika Kiyo; 1985 Dec; 31(12):2119-25. PubMed ID: 2421558
[TBL] [Abstract][Full Text] [Related]
10. Serum osteocalcin concentration in patients with prostatic cancer.
Francini G; Bigazzi S; Leone V; Gennari C
Am J Clin Oncol; 1988; 11 Suppl 2():S83-7. PubMed ID: 3266542
[TBL] [Abstract][Full Text] [Related]
11. Salmon calcitonin in the treatment of bone metastases.
Serdengeçti S; Serdengeçti K; Derman U; Berkarda B
Int J Clin Pharmacol Res; 1986; 6(2):151-5. PubMed ID: 3721646
[TBL] [Abstract][Full Text] [Related]
12. Total urinary hydroxyproline excretion before and after hypophysectomy in patients with bone metastases from breast carcinoma.
Ditzel J; Jordal R; Riskaer N
Acta Endocrinol (Copenh); 1968 Nov; 59(3):353-61. PubMed ID: 5754976
[No Abstract] [Full Text] [Related]
13. [Urine hydroxyproline, serum alkaline phosphatase, calcium and phosphorus in neoplastic diseases].
Radom S; Zulawski M; Golebiowska D
Nowotwory; 1971; 21(4):267-73. PubMed ID: 5138713
[No Abstract] [Full Text] [Related]
14. Effects of prolonged administration of porcine calcitonin in postmenopausal osteoporosis.
Jowsey J; Riggs BL; Goldsmith RS; Kelly PJ; Arnaud CD
J Clin Endocrinol Metab; 1971 Nov; 33(5):752-8. PubMed ID: 4942159
[No Abstract] [Full Text] [Related]
15. [Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer].
Rinsho K
Nihon Hinyokika Gakkai Zasshi; 1983 Jan; 74(1):76-80. PubMed ID: 6191064
[No Abstract] [Full Text] [Related]
16. Urinary hydroxyproline and plasma mucoprotein as an indication of the presence of bone metastases.
Basu TK; Donaldson D; Williams DC
Oncology; 1974; 30(3):197-203. PubMed ID: 4459734
[No Abstract] [Full Text] [Related]
17. Effects of calcitonin in metastatic bone carcinoma, osteoporosis, polyostotic fibrous dysplasia and hypercalcemia.
Morii H; Tanae A; Ibayashi H; Nakao K
Endocrinol Jpn; 1971 Feb; 17(6):81-90. PubMed ID: 4254451
[No Abstract] [Full Text] [Related]
18. Urinary hydroxyproline in healthy patients and in prostate patients with and without bone metastases.
Heller W; Harzmann R; Bichler KH; Schmidt K
Curr Probl Clin Biochem; 1979; (9):249-56. PubMed ID: 446076
[TBL] [Abstract][Full Text] [Related]
19. Bone collagen and calcium metabolism in normocalcemic and hypercalcemic patients with breast cancer.
Lee CA; Lloyd HM
Cancer; 1971 May; 27(5):1099-105. PubMed ID: 5092517
[No Abstract] [Full Text] [Related]
20. [Short-term biological effects of synthetic salmon calcitonin in Paget's disease. Influence of posology].
Chapuy MC; Meunier P; Terrier M; David L; Vignon G
Pathol Biol (Paris); 1975 May; 23(5):349-59. PubMed ID: 172838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
